Category: Obesity

The Cardiometabolic Medicine Market: Future Outlook and Industry Trends 2021 

Delaying elective surgeries and routine health services, the COVID-19 pandemic is likely to have significant effects on medicine across a broad range of specialties, however, cardiometabolic medicine may experience these implications more acutely. As many risk factors – including heightened stress levels, increased sedentary lifestyles, and decreased physical activity – are currently being perpetuated by virus-related restrictions, these regulations may alter consumer and patient behaviors for years to come.

Nonetheless, the overall global cardiometabolic medicine market is forecasted to recover quickly and continue exhibiting upward movement. Despite the potential negative short-term repercussions of pandemic-adjusted medical care, a consistent rise in the prevalence of cardiometabolic diseases among the population is expected to propel growth within the industry in the coming decade.

Cardiometabolic Medicine Market Overview

Cardiometabolic disease and its associated comorbidities are among the most prevalent diseases worldwide; according to the American Heart Association, cardiovascular disease (CVD) accounts for approximately 1 out of 3 deaths in the United States and experts predict the total number of annual deaths attributable to CVD will exceed 23.6 million by 2030. Furthermore, researchers estimate that over half a billion individuals across the globe will be affected by obesity and diabetes by the year 2040.

Due to increased awareness and a greater availability of treatment options, some of these diseases no longer lead to fatal outcomes. As such, effective treatments are expected to contribute to market growth while research efforts focus on the development of new therapeutic options and subsidized pricing makes these drugs more accessible to a wider range of patients.

The cardiovascular drug market is anticipated to exhibit a compound annual growth rate of 3.8% to reach a value of $63.96 billion by 2026. At the same time, the global metabolic disorder therapeutics market size is expected to register a CAGR of nearly 8% growing to a value of approximately $89 billion in 2025. Key factors driving growth in the metabolic disorder sector is the increasing demand for one-time therapies and rising prevalence of lifestyle diseases.

Market Sectors and Their Driving Factors 

The Cardiovascular Drug Market 

One important sector of the cardiometabolic medicine market is expected to grow at a compound annual growth rate of 3% to ultimately reach a value of $106.1 billion by 2023. Fueled by an increased demand for effective therapeutics, upward movement in the cardiovascular drug market can be primarily attributed to the increased awareness of serious implications of CVD on human health. Improved understanding of cardiometabolic health as well as continued research and development efforts will contribute to the introduction of new therapeutics and technologies in the coming years, furthering industry expansion.

Additionally, the innovation and development of new therapeutics that target diseases more efficiently will fuel the upward trend in the cardiovascular drug market. At the same time, decreases in rates of cardiac surgeries and consultations due to re-scheduling, cancellations, no-shows, and COVID-19 restrictions are expected to sustain and potentially elevate demand for cardiovascular pharmacologic treatments as interim solutions.

The Obesity and Metabolic Disorder Sector 

Showing no signs of slowing own, the obesity epidemic will continue to drive rising industry value with the obesity treatment market forecasted to reach nearly $20 billion by 2026. While the United States maintains its position as the leader in obesity cases across industrial countries, cases of diabetes are steadily increasing are rising across the globe and putting many nations at risk for potential metabolic disorder epidemics.

As such, the metabolic disorder market sector is anticipated to continue its upward trend propelled by a rapidly aging population, increasingly sedentary lifestyles, rising cases of smoking and other metabolic pathway restricting practices, as well as heightened public awareness of these conditions and their long-term health consequences.

The Diabetes Drug Market

Diabetes has now become a global epidemic with over 5% of the population affected by the disease requiring constant medication. Current statistics indicate that approximately 34.2 million people in the United States have diabetes while many more remain undiagnosed and unaware of their condition. Alongside the rise in obesity, the growing adoption of a sedentary lifestyle and increasing consumption of unhealthy foods are likely to continue upward trends in prevalence and boost the diabetes drug market in the coming years.

North America currently generates the highest market revenue at approximately $24 million and is expected to dominate throughout the forecast period. However, Europe is anticipated to be the second most prominent region based on revenue by the year 2026. Market growth across the globe is likely to be fueled by the emergence of novel therapeutic products, including the insulin segment with more accessible therapeutics made available to patients. Growing investments in research and development spearheaded by government initiatives are anticipated to support the market sector and its rapid surge in the near future.

Established and Emerging Markets

The two leading players in the global cardiometabolic disease market are North America and Europe, the largest markets expected to hold their position as a result of high availability of skilled professionals and the presence of a large number of key market players in these regions.

Due to the high prevalence of cardiometabolic disease in China, the nation is expected to provide a significant market opportunity in the Asia Pacific region. This emerging market will boast increases and improvements in healthcare infrastructure, rising awareness about cardiometabolic health problems among the population, as well as growing demand for therapeutic options.

Additionally, major market vendors are increasingly seeking to expand their business geographically and in particular, in developing nations. Not only will this provide better medical care to people in developing nations but also provide growth incentives in the market, which will be fueled by mergers and acquisitions as well as investments in research and development during the coming years.

In addition to the aforementioned driving factors, the cardiometabolic medicine industry is also expected to benefit from the continued growth of the telemedicine sector in 2021 and beyond. Offering the opportunity for chronic disease management outside of the practice setting, telemedicine alongside various health technologies and tools are expected to fuel industry expansion as advances in digital infrastructure make these services more efficient and accessible to the general patient population. Despite potential challenges in the near-term, the cardiometabolic medicine market has a positive future outlook with significant growth projected in the forthcoming decade.

Disparities in Obesity Management in Primary Care

Currently, around 90 million U.S. adults are classified as obese with a disproportionate amount of socioeconomically disadvantaged individuals affected. As recently proven, obesity can worsen COVID-19 outcomes alongside increasing the risk of cardiometabolic conditions, cardiovascular disease, type 2 diabetes, and other health conditions. Despite the significant disease burden placed on population health and the public health system, the management of obesity in primary care settings continues to lag behind that of other chronic conditions. Only recently has obesity become formally recognized as a disease, highlighting the need for improved prevention and treatment protocols across demographics and increased accessibility.

Obesity Management in Primary Care Clinics

Recently published in the New England Journal of Medicine, results of the Promoting Successful Weight Loss in Primary Care in Louisiana (PROPEL) trial advance the current knowledge regarding obesity management in primary care settings. The findings elucidate both the scope and intensity of interventions with a focus on underserved demographics.

The cluster-randomized trial examined data from 803 adults (67% black, 84% women) recruited from 18 primary care clinics across Louisiana. Participants were assigned to two groups, usual care and intensive-lifestyle intervention. Patients in the usual care cohort received routine medical care and health education materials throughout the course of the 24-month trial. Meanwhile, participants designated part of the intensive-lifestyle group received weekly counseling, personalized care, and tailored recommendations. This cohort received weekly counseling with 16 sessions conducted in person and 6 over telephone during the first 6 months of the trial. Afterward, they had monthly sessions through month 24.

Health coaches were trained by the research team and embedded in the primary care setting to deliver care and give patients personalized food-intake and calorie-intake targets. Patients were to weigh themselves daily using digitally connected scales and their nutritional and physical patterns were adjusted to help them meet their weight goals.

Intensive Lifestyle Interventions Show Real Results 

The study’s author noted a significant improvement in meeting weight loss targets when combined with strategic expert care. At the 12-month benchmark point, participants in the intensive-lifestyle group lost a mean of 6.75% of their baseline weight while those in the usual-care group only lost an average of 0.59%. In addition, participants within the intensive-lifestyle cohort reported significant improvements in multiple components of quality of life, including physical function and work.

Overall, the researchers’ findings revealed black patients lost approximately 2% less weight than patients of other races and ethnic groups at the 12-month mark. For the time being, the reasons for this disparity are unknown but experts believe they may include a lower resting energy expenditure in black women compared with that of their non-Hispanic white counterparts.

Out of the 803 total participants, 50.7% reduced their baseline weight by at least 5% – the best categorical weight losses observed in primary care studies, especially those involving socioeconomically disadvantaged patients. “Although patients in the intensive-lifestyle group in the PROPEL trial, on average, regained weight from month 12 to month 24, most likely because of the reduced frequency of counseling visits, they nevertheless maintained a mean 5% reduction at month 24,” the study’s authors noted.

The findings from the latest PROPEL trial reveal that it is possible for socioeconomically disadvantaged persons to lose clinically substantial amounts of weight when provided the intensive behavioral therapy and professional support necessary in primary care settings. The issue of how to ensure that all Americans, including those in underserved areas, receive the same reimbursed care for weight management that they have for other chronic conditions that stem from obesity – the root of the problem. The current lack of such targeted, accessible care contributes to the growing burden of widening health disparities in the nation which are only becoming more apparent in the face of a public health crisis.